Recruiting

Testing two radioactive drugs together for advanced prostate cancer

Plain-English translation of NCT04886986 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Read our Prostate Cancer research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage trial testing a new combination treatment for men with advanced prostate cancer that has stopped responding to hormone therapy. The trial combines two radioactive medications called and 177Lu-PSMA to see if they work better together than either drug alone. Researchers will also measure how safe this combination is and what side effects patients experience.

Men with advanced prostate cancer often run out of treatment options after standard therapies stop working. This medication combination targets cancer cells in a new way, and doctors hope that using two radioactive drugs together might help patients whose cancer has become resistant to other treatments.

Do you qualify?

You likely qualify if…

you have been diagnosed with prostate cancer that has spread to other parts of your body and is continuing to grow
you have already received at least one hormone-blocking therapy (such as enzalutamide or abiraterone acetate)
you have either received chemotherapy, been told you cannot receive it, or chose not to receive it
you are 18 years or older with adequate kidney, liver, heart, and bone marrow function
you have low testosterone levels (maintained through ongoing hormone therapy if you haven't had surgery to lower it)

You likely don't qualify if…

you have received prior radioactive therapy for prostate cancer targeting PSMA (except for imaging scans)
you have cancer that has spread to your brain or the lining of your spine
you have had blood clots in your legs or lungs within the past month
you are currently enrolled in another cancer treatment study or received an investigational drug within the past 4 weeks
you have serious heart, lung, kidney, or liver disease that would prevent you from safely completing the trial

What participation looks like

You would receive two radioactive medications as injections every 8 weeks, with a total of 2 treatment cycles planned. Throughout the trial, you'll have regular blood tests, imaging scans, and check-ups to monitor how the treatment is working and watch for any side effects. The study involves visits to the hospital or clinic over several months, with the research team closely tracking your health and cancer response.

AI-generated summary from trial data · Jun 30, 2026 · Not medical advice

Trial locations(2 sites)

United States

Brooklyn Methodist Hospital - New York Presbyterian, Brooklyn, New York

Weill Cornell Medicine New York Presbyterian, New York, New York